for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Puretech Health PLC

PRTC.L

現在値

401.50GBp

変化

-1.50(-0.37%)

出来高

101,922

本日のレンジ

397.50

 - 

420.00

52週レンジ

210.75

 - 

447.66

∙ 約20分前の相場を表示しています。

適時開示

Puretech Health FY Operating Loss Of $119.5 Mln

April 15 (Reuters) - PureTech Health PLC <PRTC.L>::PLC - FINAL RESULTS.FY TOTAL REVENUE OF $11.7 MILLION VERSUS $9.8 MILLION.FY OPERATING LOSS OF $119.5 MILLION VERSUS $135.4 MILLION.HAVE NOT DECLARED DIVIDENDS AND WE DO NOT PLAN TO PAY ANY DIVIDENDS IN FUTURE.

Puretech Health Says Stephen Muniz To Retire As Chief Operating Officer

March 18 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH PLC - DIRECTORATE CHANGE.STEPHEN MUNIZ, ESQ., WILL RETIRE FROM HIS ROLE AS CHIEF OPERATING OFFICER AND CORPORATE SECRETARY.

Puretech Health Notes Karuna Pricing $250 Mln Public Offering

March 2 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH PLC - KARUNA PRICES APPROXIMATELY $250M PUBLIC OFFERING.

PureTech Health Says Vedanta Biosciences Appointed Mark Mullikin As CFO

Feb 8 (Reuters) - PureTech Health PLC <PRTC.L>::VEDANTA BIOSCIENCES APPOINTS MARK MULLIKIN AS CHIEF FINANCIAL OFFICER.VEDANTA BIOSCIENCES - MULLIKIN JOINS VEDANTA FROM EDITAS MEDICINE, WHERE HE SERVED AS VICE PRESIDENT, FINANCE.

PureTech Founded Entity Vor Biopharma Announces Pricing Of Initial Public Offering

Feb 5 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH FOUNDED ENTITY VOR BIOPHARMA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING.SAYS INITIAL PUBLIC OFFERING OF 9.83 MILLION COMMON SHARES PRICED AT $18.00PER SHARE.

PureTech Health Syas Vor Files IPO Registration Statement On Nasdaq

Jan 18 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH PLC - VOR FILES IPO REGISTRATION STATEMENT ON NASDAQ.

PureTech Health Appoints George Farmer As CFO

Jan 5 (Reuters) - PureTech Health PLC <PRTC.L>::APPOINTMENT OF GEORGE FARMER, PH.D., AS CHIEF FINANCIAL OFFICER.

Puretech Health Starts LYT-200 Clinical Trial In Solid Tumors

Dec 11 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH PLC - PRTC STARTS LYT-200 CLINICAL TRIAL IN SOLID TUMORS.PURETECH HEALTH - TRIAL WILL ASSESS SAFETY AND TOLERABILITY OF ESCALATING DOSES OF LYT-200 WITH RESULTS EXPECTED IN Q4 2021.

PureTech Initiates Phase 2a trial of LYT-100 in Lymphedema

Dec 10 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH - PURETECH INITIATES PHASE 2A TRIAL OF LYT-100 (DEUPIRFENIDONE) IN LYMPHEDEMA.PURETECH HEALTH - STUDY WILL FURTHER EVALUATE SAFETY AND TOLERABILITY OF LYT-100.PURETECH HEALTH - STUDY WILL EXPLORE CLINICAL EFFICACY ENDPOINTS IN PATIENTS WITH BREAST-CANCER RELATED, UPPER LIMB SECONDARY LYMPHEDEMA.PURETECH HEALTH - SEPARATE PHASE 2 STUDY EVALUATING LYT-100 IN LONG COVID RESPIRATORY COMPLICATIONS AND RELATED SEQUELAE WAS RECENTLY INITIATED.PURETECH HEALTH - REGISTRATION-ENABLING STUDIES ARE ALSO BEING PLANNED FOR LYT-100 IN IDIOPATHIC PULMONARY FIBROSIS (IPF).PURETECH HEALTH - RESULTS FROM THIS PROOF-OF-CONCEPT STUDY ARE EXPECTED IN Q4 OF 2021.

Puretech Health Says Guidance For Exchanging Ordinary Shares Into ADSS

Nov 13 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH PLC - GUIDANCE FOR EXCHANGING ORDINARY SHARES INTO ADSS.PURETECH HEALTH- NASDAQ HAS APPROVED ADSS FOR LISTING, & ADSS ARE EXPECTED BEGIN TRADING ON NASDAQ GLOBAL MARKET UNDER SYMBOL "PRTC" ON 16 NOV 2020.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up